Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, Kluger HM. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clinical Pathology 2013, 13: 3. PMID: 23374878, PMCID: PMC3575219, DOI: 10.1186/1472-6890-13-3.Peer-Reviewed Original ResearchRenal cell carcinoma tumorsMetastatic tumorsCarcinoma tumorsMetastatic specimensPredictive biomarker developmentFGF-R1Predictive biomarker testingRenal cell carcinomaTissue microarray blocksResultsNo significant differencesKi67-positive cellsMore Ki67-positive cellsSignificant differencesCell carcinomaBiomarker testingPDGF-RβMicroarray blocksPositive cellsQuantitative immunofluorescence methodVEGF-R3VEGF-R1Expression of targetsTumorsImmunofluorescence methodPrimary specimensVascularity of primary and metastatic renal cell carcinoma specimens
Aziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, Kluger HM. Vascularity of primary and metastatic renal cell carcinoma specimens. Journal Of Translational Medicine 2013, 11: 15. PMID: 23316728, PMCID: PMC3561185, DOI: 10.1186/1479-5876-11-15.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaMicrovessel areaMetastatic samplesCell carcinomaMetastatic sitesPrimary tumorMetastatic renal cell carcinomaRenal cell carcinoma tumorsClear cell tumorsClear cell carcinomaPredictive biomarker studiesAnti-angiogenic drugsAnti-angiogenic therapyTypes of tumorsHigh response ratePrimary nephrectomyHistologic subtypeCell tumorsDifferent histologyPapillary histologyCD 34Variable histologyClinical studiesClear cellsTumor vascularity